249 related articles for article (PubMed ID: 34732383)
21. Distinct effects of sucrose and trehalose on protein stability during supercritical fluid drying and freeze-drying.
Jovanović N; Bouchard A; Hofland GW; Witkamp GJ; Crommelin DJ; Jiskoot W
Eur J Pharm Sci; 2006 Mar; 27(4):336-45. PubMed ID: 16338123
[TBL] [Abstract][Full Text] [Related]
22. Stability study perspective of the effect of freeze-drying using cryoprotectants on the structure of insulin loaded into PLGA nanoparticles.
Fonte P; Soares S; Sousa F; Costa A; Seabra V; Reis S; Sarmento B
Biomacromolecules; 2014 Oct; 15(10):3753-65. PubMed ID: 25180545
[TBL] [Abstract][Full Text] [Related]
23. Effects of formulation and process variables on the aggregation of freeze-dried interleukin-6 (IL-6) after lyophilization and on storage.
Lueckel B; Helk B; Bodmer D; Leuenberger H
Pharm Dev Technol; 1998 Aug; 3(3):337-46. PubMed ID: 9742554
[TBL] [Abstract][Full Text] [Related]
24. Impact of dextran on thermal properties, product quality attributes, and monoclonal antibody stability in freeze-dried formulations.
Haeuser C; Goldbach P; Huwyler J; Friess W; Allmendinger A
Eur J Pharm Biopharm; 2020 Feb; 147():45-56. PubMed ID: 31866444
[TBL] [Abstract][Full Text] [Related]
25. Freeze-dried whole plasma: evaluating sucrose, trehalose, sorbitol, mannitol and glycine as stabilizers.
Bakaltcheva I; O'Sullivan AM; Hmel P; Ogbu H
Thromb Res; 2007; 120(1):105-16. PubMed ID: 16962645
[TBL] [Abstract][Full Text] [Related]
26. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody.
Cleland JL; Lam X; Kendrick B; Yang J; Yang TH; Overcashier D; Brooks D; Hsu C; Carpenter JF
J Pharm Sci; 2001 Mar; 90(3):310-21. PubMed ID: 11170024
[TBL] [Abstract][Full Text] [Related]
27. Freeze-drying of mannitol-trehalose-sodium chloride-based formulations: the impact of annealing on dry layer resistance to mass transfer and cake structure.
Lu X; Pikal MJ
Pharm Dev Technol; 2004; 9(1):85-95. PubMed ID: 15000469
[TBL] [Abstract][Full Text] [Related]
28. Applications of Freezing and Freeze-Drying in Pharmaceutical Formulations.
Izutsu KI
Adv Exp Med Biol; 2018; 1081():371-383. PubMed ID: 30288720
[TBL] [Abstract][Full Text] [Related]
29. Application of disaccharides alone and in combination, for the improvement of stability and particle properties of spray-freeze dried IgG.
Daneshmand B; Faghihi H; Amini Pouya M; Aghababaie S; Darabi M; Vatanara A
Pharm Dev Technol; 2019 Apr; 24(4):439-447. PubMed ID: 30070161
[TBL] [Abstract][Full Text] [Related]
30. Significant Drying Time Reduction Using Microwave-Assisted Freeze-Drying for a Monoclonal Antibody.
Gitter JH; Geidobler R; Presser I; Winter G
J Pharm Sci; 2018 Oct; 107(10):2538-2543. PubMed ID: 29890173
[TBL] [Abstract][Full Text] [Related]
31. Cyclodextrin as membrane protectant in spray-drying and freeze-drying of PEGylated liposomes.
van den Hoven JM; Metselaar JM; Storm G; Beijnen JH; Nuijen B
Int J Pharm; 2012 Nov; 438(1-2):209-16. PubMed ID: 22960501
[TBL] [Abstract][Full Text] [Related]
32. Well-plate freeze-drying: a high throughput platform for screening of physical properties of freeze-dried formulations.
Trnka H; Rantanen J; Grohganz H
Pharm Dev Technol; 2015 Jan; 20(1):65-73. PubMed ID: 24417680
[TBL] [Abstract][Full Text] [Related]
33. Effects of additives on the stability of recombinant human factor XIII during freeze-drying and storage in the dried solid.
Kreilgaard L; Frokjaer S; Flink JM; Randolph TW; Carpenter JF
Arch Biochem Biophys; 1998 Dec; 360(1):121-34. PubMed ID: 9826437
[TBL] [Abstract][Full Text] [Related]
34. Freeze-drying of nanosuspensions, part 3: investigation of factors compromising storage stability of highly concentrated drug nanosuspensions.
Beirowski J; Inghelbrecht S; Arien A; Gieseler H
J Pharm Sci; 2012 Jan; 101(1):354-62. PubMed ID: 21905035
[TBL] [Abstract][Full Text] [Related]
35. Effect of Arginine on the Aggregation of Protein in Freeze-Dried Formulations Containing Sugars and Polyol: 1-Formulation Development.
Hackl E; Darkwah J; Smith G; Ermolina I
AAPS PharmSciTech; 2018 Feb; 19(2):896-911. PubMed ID: 29047017
[TBL] [Abstract][Full Text] [Related]
36. Freeze-drying of low molecular weight poly(L-lactic acid) nanoparticles: effect of cryo- and lyoprotectants.
Hirsjärvi S; Peltonen L; Kainu L; Hirvonen J
J Nanosci Nanotechnol; 2006; 6(9-10):3110-7. PubMed ID: 17048525
[TBL] [Abstract][Full Text] [Related]
37. Formulation, process, and storage strategies for lyophilizates of lipophilic nanoparticulate systems established based on the two models paliperidone palmitate and solid lipid nanoparticles.
Trenkenschuh E; Savšek U; Friess W
Int J Pharm; 2021 Sep; 606():120929. PubMed ID: 34303819
[TBL] [Abstract][Full Text] [Related]
38. Formulation development of freeze-dried oligonucleotide-loaded gelatin nanoparticles.
Zillies JC; Zwiorek K; Hoffmann F; Vollmar A; Anchordoquy TJ; Winter G; Coester C
Eur J Pharm Biopharm; 2008 Oct; 70(2):514-21. PubMed ID: 18582569
[TBL] [Abstract][Full Text] [Related]
39. Excipients for Room Temperature Stable Freeze-Dried Monoclonal Antibody Formulations.
Haeuser C; Goldbach P; Huwyler J; Friess W; Allmendinger A
J Pharm Sci; 2020 Jan; 109(1):807-817. PubMed ID: 31622600
[TBL] [Abstract][Full Text] [Related]
40. Screening of novel excipients for freeze-dried protein formulations.
Holm TP; Meng-Lund H; Rantanen J; Jorgensen L; Grohganz H
Eur J Pharm Biopharm; 2021 Mar; 160():55-64. PubMed ID: 33508435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
